Medulloblastoma is one of the most common malignant pediatric brain tumors that accounts for approximately 70% of all embryonal CNS tumors from 0 to 19 years.
Researchers from Shenzhen University and affiliated organizations detailed the preclinical characterization of a synergistic intravesical instillation of fenbendazole (FBZ) and CRISPR-Cas13a-based nanoplatform as a new strategy for the treatment of bladder cancer.
Suven Life Sciences Ltd. has received IND approval from the FDA allowing it to initiate a first-in-human phase I study of SUVN-I6107, a muscarinic M1 receptor positive allosteric modulator (PAM) as a potential new treatment to address the dementia market.
Mestag Therapeutics Ltd. has been awarded a £1.5 million ($1.9 million) grant from Innovate UK’s Cancer Therapeutics program to accelerate the development of MST-0300.
Pulmonary arterial hypertension (PAH) is a progressive disorder where high pulmonary artery pressure and vascular resistance lead to progressive dyspnea, and right ventricular hypertrophy (RVH).
Eydisbio Inc. has been awarded a $2.6 million phase II Small Business Innovation Research (SBIR) grant from the National Institute of Health’s (NIH) National Heart, Lung, and Blood Institute (NHLBI) to support its ongoing research into the efficacy of TAK1 inhibition in animal models of systemic sclerosis.
Bayer AG and Nextrna Therapeutics Inc. have entered into a collaboration and license agreement to develop small-molecule therapeutics targeting long noncoding RNAs (lncRNAs) in oncology. Under the agreement, Bayer gains access to Nextrna’s differentiated approach to inhibit the function of lncRNAs by disrupting the interaction between lncRNAs and RNA-binding proteins (RBPs) with small molecules.
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide and is characterized by an abnormal inflammatory reaction of the lungs to inhaled particles, such as cigarette smoke. On the other hand, the transcription factor interferon responsive factors (IRFs) are key elements in the production of type I and III interferons. A group of researchers in Italy looked into the relationship between interferon regulatory factor 3 (IRF3) and COPD outcomes.
Since the publication of The Hallmarks of Aging in 2013, aging research has exploded. The field now has more than 300,000 articles on the biological signals of the effect of time on the body. What would Marty McFly, the legendary character from the Back to the Future saga who traveled with his DeLorean time machine from the ‘80s to the ‘50s, think if he visited 2024 and saw laboratories experimenting with techniques to turn back the biological clocks of cells or increase the lifespan of rejuvenated mice?
RSS
